A case of successful using a stromal corneal transplant for therapeutic keratoplasty in a patient with herpetic keratitis

2018 ◽  
Vol 73 (2) ◽  
pp. 56-59
Author(s):  
E. Sereda ◽  
◽  
G. Drozhzhyna ◽  
T. Gaidamaka ◽  
◽  
...  
2009 ◽  
Vol 21 (5) ◽  
pp. 10-14
Author(s):  
P. Bezdetko ◽  
E. Iiyina ◽  
M. Lisenko ◽  
◽  
◽  
...  

2021 ◽  
Vol 32 ◽  
pp. 73-76
Author(s):  
Alberto E. Paniz-Mondolfi ◽  
Steven Agemy ◽  
Connie Cañete-Gibas ◽  
Melissa R. Gitman ◽  
Codrin E. Iacob ◽  
...  

1996 ◽  
Vol 40 (10) ◽  
pp. 2327-2331 ◽  
Author(s):  
W J O'Brien ◽  
J L Taylor ◽  
H Ankel ◽  
G Sitenga

Prostaglandin A2 (PGA2) inhibited the replication of herpes simplex virus type 1 in rabbit and human cornea stromal cells at concentrations of 1 to 5 microM while causing significant toxicity at 55 to 150 microM. Despite favorable therapeutic indices in cultured cells, PGA2 was not effective as a therapeutic agent in the treatment of herpetic keratitis in a rabbit model. The sequelae of disease appeared more severe in animals receiving PGA2 than in untreated or placebo-treated controls. The recovery of virus from tissues of latently infected rabbits was not affected by therapy. PGA2 therapy alone induced breakdown of the blood-aqueous barrier, indicating that pharmacologically active concentrations of drug were achieved in the eye. Thus, PGA2 had antiviral activity, but its proinflammatory effects appeared to be more detrimental than beneficial in the treatment of herpetic keratitis.


1980 ◽  
Vol 98 (10) ◽  
pp. 1755-1759 ◽  
Author(s):  
L. M. Cobo ◽  
D. J. Coster ◽  
N. S. C. Rice ◽  
B. R. Jones

2013 ◽  
Vol 208 (9) ◽  
pp. 1359-1365 ◽  
Author(s):  
Monique van Velzen ◽  
David A. M. C. van de Vijver ◽  
Freek B. van Loenen ◽  
Albert D. M. E. Osterhaus ◽  
Lies Remeijer ◽  
...  

1965 ◽  
Vol 59 (3) ◽  
pp. 473-476 ◽  
Author(s):  
Bernard B. Zucker ◽  
Andre J. Nahmias ◽  
Sidney Kibrick
Keyword(s):  

1988 ◽  
Vol 106 (4) ◽  
pp. 463-466 ◽  
Author(s):  
Stephen M. Goode ◽  
Ellen Hertzmark ◽  
Roger F. Steinert

2021 ◽  
Vol 1 (1) ◽  
Author(s):  
Mine Esen Baris

INTRODUCTION: To compare the surgical outcomes of anterior chamber (AC) and posterior chamber (PC) implantation of iris claw lens (ICL) combined with penetrating corneal transplantation (P-CT), in eyes with no capsular support. METHODS: The records of 20 P-CT cases who underwent ICL implantation were retrospectively evaluated. The eyes were grouped according to the location of implantation; AC ICL and PC ICL. Pre- and post-surgical best-corrected visual acuity (BCVA), post-operative complications and graft rejection rates were compared between the two groups. Mean follow-up time was 28 (range, 12 and 76) months. RESULTS: ICLs were implanted during P-CT surgery in 14 (70%) eyes, and as a secondary procedure after P-CT in 6 (30%) eyes. ICLs were implanted in PC in 12 (60%) and in AC in 8 (40%) eyes. Mean preoperative BCVA was 0.064 (range, 0.001-0.02) in PC group and 0.02 (range, 0.001-0.1) in AC group (p=0.86). Mean postoperative BCVA was 0.17 (range, 0.0001-1.0) in PC group and 0.14 (range, 0.0001-0.4) in AC group (p=0.81). Glaucoma developed in 5 (41.6%) eyes with PC ICL. No eye with AC ICL developed glaucoma over time. DISCUSSION AND CONCLUSION: Both AC and PC ICL implantation provide favorable visual outcomes and complication rates in CT patients. However, PC implantation of ICL seems to increase glaucoma incidence.


Sign in / Sign up

Export Citation Format

Share Document